



NEWS RELEASE

NeuroVive appoints Chief Operating Officer

Note: This is an English version of a press release communicated by NeuroVive 2013-02-01

Lund (Sweden) – February 1, 2013. NeuroVive, a leading mitochondrial medicine company, is pleased to announce the appointment of Jan Nilsson as Chief Operating Officer (COO). Jan will oversee the day-to-day operations of the Company and support the planned commercialisation of CicloMulsion® and NeuroSTAT®, NeuroVive's leading products for the treatment of acute cardiovascular and neurological conditions through mitochondrial protection.

Jan has over 30 years of experience in senior management, commercial and sales roles in the pharmaceutical and biotechnology sectors in Sweden and internationally. Since 2011 Jan has served as Managing Director of Lipopeptide AB and as Chief Commercial Officer at Pergamum AB, two clinical-stage Swedish biotech companies developing innovative wound treatments based on therapeutic peptides. Between 2004 and 2009 Jan served as Managing Director of Tripep AB, a listed Swedish-biotech company developing therapeutic DNA-vaccines against hepatitis B and C. Prior to that Jan spent several years at Schering-Plough where he served in a number of senior management, marketing and sales positions, including Vice-President for the Nordic region between 2000 and 2004. Jan has served on the Board of Directors of NeuroVive since 2011. As a result of his new role, Jan will not be standing for re-election to the NeuroVive Board at the next Annual Meeting.

CicloMulsion® and NeuroSTAT® are in clinical development by NeuroVive for the treatment of heart reperfusion injury and traumatic brain injury respectively. These are indications of huge medical need for which there are currently no approved pharmaceutical treatment options.

Both products act to prevent the death of mitochondria in damaged cells and the cascade of intracellular biochemical events that lead to secondary tissue damage following a traumatic injury. By protecting a cell's mitochondria NeuroVive's products ensure that energy production is preserved and a damaged cell's normal regenerative mechanisms can act to repair and maintain the cell.

Mikael Bronnegard, CEO of NeuroVive Pharmaceutical said: *"I am delighted to have appointed Jan Nilsson to the position of Chief Operating Officer, significantly strengthening our senior management team during what is a very exciting period in NeuroVive's development. With CicloMulsion® currently in Phase III clinical trial, NeuroSTAT® now entering a Phase IIa clinical study and the recent collaboration agreement with Sihuan Pharmaceutical for the commercialization of these products in China, NeuroVive is making significant strides forward in the execution of our product development and commercial strategies. Jan is an excellent addition to NeuroVive's management team and one that will help to drive the Company towards the further realization of its corporate goals and to maximize shareholder value by delivering our novel medicines to market."*

About NeuroVive Pharmaceutical AB

NeuroVive Pharmaceutical AB (www.neurovive.com) a leading mitochondrial medicine company is developing a portfolio of products to treat acute cardiovascular and neurological conditions through mitochondrial protection.

NeuroVive's leading products are special formations of the cyclophilin inhibitor cyclosporine, which act to limit secondary tissue damage caused by myocardial infarction and traumatic brain injuries by preventing the destruction of mitochondria in distressed cells and the cascade of intracellular biochemical events that lead to cell death.

NeuroVive's lead product is CicloMulsion®, the first cyclophilin inhibitor for the treatment of reperfusion injuries. CicloMulsion® is currently in a 1000 patient Phase III clinical trial evaluating its ability to reduce reperfusion injuries in patients with myocardial infarction.

NeuroVive is also developing NeuroSTAT®, which is entering a Phase IIa clinical trial in patients with severe traumatic brain injury. Both indications have huge medical need and for which there are currently no approved pharmaceutical treatment options.

NeuroVive's pipeline also includes a cyclophilin inhibitor for stroke and drug candidates that act on mitochondria to address energy regulation disorders.

NeuroVive's shares are listed on the Swedish trading platform AktieTorget (www.aktietorget.se). The AktieTorget market is focused on emerging, entrepreneurial businesses through an electronic trading system supplied by the OMX Nordic stock exchange in Stockholm, Sweden.

Media and investor relations contacts

NeuroVive Pharmaceutical: Mikael Bronnegard
Email: info@neurovive.com
Phone No: +46 (0) 70 299 62 64

Citigate Dewe Rogerson: Nina Enegren / David Dible
Email: nina.enegren@citigatedr.co.uk
Phone No: +44 207 282 1050